Molecular Pharmacology Program

The David Scheinberg Lab

David A. Scheinberg, MD, PhD

Chair, Center for Experimental Therapeutics, MSK; Deputy Director, Sloan Kettering Institute, for Therapeutic Discovery

The overall goals of this laboratory are to develop novel targeted immunotherapies based on effectors of the immune system and to understand their mechanisms of action as well as the mechanisms of resistance to them. This includes antibodies, targeted nano-devices, engineered cells, and active specific agents such vaccines. An important goal is to take these new therapies into human clinical trials for testing. Examples include a molecular nanogenerator that releases alpha particles inside cancer cells, now being tested in Phase II human trials (Blood, 2010), and a vaccine to WT1 in Phase III trials. Read full article in Science.

We have developed targeted alpha particle therapies, targeted beta emitters, oncogenic protein peptide vaccines, humanized antibodies, each of which reached human clinical trials; More recently we have discovered TCR mimic antibodies to intracellular proteins (Science Trans. Med., 2013), (Nature Biotech., 2015), as well as prototype targeted nano-machines (Nature Nano, 2013), and cellular micropharmacies (Nature Chem.Biol., 2021).

Research Projects

Projects

Featured News

David Scheinberg, Chairman, Molecular Pharmacology and Chemistry Program

At Work: Center for Experimental Therapeutics Chair David Scheinberg

A second-generation physician-scientist, David Scheinberg specializes in caring for patients with leukemia — and developing new ways to treat it.

Announcement

Pictured: Laurie Glimcher, Craig Thompson, Marc Tessier-Lavigne & Tadataka Yamada

Innovative Partnership Will Speed Drug Discovery and Development

Memorial Sloan Kettering is joining with two other academic institutions in a pioneering collaboration to speed early-stage drug discoveries into therapies for patients.

Scientists ID Antibody That Might Boost Cancer Therapy

Physician-scientist David Scheinberg discussed his discovery of a unique monoclonal antibody, a molecule that can be engineered to target specific prot...

View All Featured News

Publications Highlights

Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T, Scott A, Whitten J, Maslak P, Casey E, Tan T, Liu H, Zakhaleva V, Curcio M, Doubrovina E, O’Reilly RJ, Liu C, Scheinberg DA. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Science translational medicine. 2013;5(176):176ra33. Doi: 10.1126/scitranslmed.3005661. PubMed. PMCID: PMC3963696.

Dao T, Pankov D, Scott A, Korontsvit T, Zakhaleva V, Xu Y, Xiang J, Yan S, de Morais Guerreiro MD, Veomett N, Dubrovsky L, Curcio M, Doubrovina E, Ponomarev V, Liu C, O’Reilly RJ, Scheinberg DA. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nature biotechnology. 2015;33(10):1079-86. Doi: 10.1038/nbt.3349. PubMed PMID: 26389576; PMCID: PMC4600043.

View All Publications

People

David A. Scheinberg, MD, PhD

Chair, Center for Experimental Therapeutics, MSK; Deputy Director, Sloan Kettering Institute, for Therapeutic Discovery

Molecular Pharmacology Program Member David Scheinberg focuses on the discovery and development of novel, specific immunotherapeutic agents and targeted nanodevices for cancer therapy.
MD, PhD, Johns Hopkins University School of Medicine

scheinbd@mskcc.org: Email Address
646-888-2190: Office Phone
View physician profile: Physician profile

Members

Michael McDevitt — Michael R. McDevitt
Laboratory Member

Josh Jaeyop Lee
Hematology/Oncology Fellow

Kaitlyn Pierpont

Graduate Student

Sarah Qureshy
Medical Student Research Fellow Education

Ekaterina Revskaya
Senior Research Scientist

Patrick Wallisch, MSc — Patrick Wallisch
Graduate Student

Lab Alumni

Emily C. Casey, BS — Emily C. Casey
Principal Scientific Communication Lead at Genentech, San Francisco, CA

Thomas J. Gardner, PhD — Thomas J. Gardner
Research Fellow

William Maguire

Graduate Student

Prabodhika Mallikaratchy, PhD — Prabodhika Mallikaratchy
Visiting Scientist

Justin J. Mulvey

Graduate Student

Andrew Scott

Research Technician

Jonathan Seideman

Graduate Student

Nicholas Veomett

Graduate Student

Carlos Villa

Graduate Student

Sam Wong

Graduate Student

Victoriya Zakhaleva, Research Technician — Victoriya Zakhaleva
Research Technician

Mamadou A. Bah
Lab Rotation SEP-DEC 2020

Barbara de Mello — Barbara De Mello
Research Assistant

Michael X. Lau
Pediatric Hematology/Oncology Fellow

Manish Malviya
Senior Research Scientist

Lab Affiliations

Lab News & Events

Journal Club & Photo Album

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Get in Touch

scheinbd@mskcc.org

Lab Head Email
646-888-2190

Office Phone
646-888-2205

Lab Phone

Lab Resources

To learn more about Postdoc compensation and benefits at MSK, please visit https://www.mskcc.org/education-training/postdoctoral/resources-postdocs/compensation-benefits-resources

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

David A. Scheinberg discloses the following relationships and financial interests:

Actinium
Equity; Intellectual Property Rights; Professional Services and Activities
Arvinas, Inc.
Equity
Atengen, Inc.
Equity; Professional Services and Activities (Uncompensated)
Clade Therapeutics, Inc.
Intellectual Property Rights
Eureka Therapeutics Inc
Equity; Professional Services and Activities
Great Point Partners
Equity; Professional Services and Activities
Iovance Biotherapeutics, Inc.
Equity

Lantheus Medical Imaging, Inc.
Equity
Lilly Oncology
Equity
Pfizer, Inc.
Equity
Repertoire Immune Medicines, Inc.
Professional Services and Activities
Sapience Therapeutics, Inc.
Equity; Fiduciary Role / Position
Sellas Life Science Group
Equity; Fiduciary Role / Position; Intellectual Property Rights

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.

View all disclosures